Aspargo Labs Appoints Harold D. Tamayo as CFO for Public Market Entry

Aspargo Labs Inc., a New York-based specialty pharmacy and MedTech company, has announced the appointment of Harold D. Tamayo as their Chief Financial Officer. Tamayo, who holds an MBA and a master's in industrial engineering, has an impressive track record in financial leadership and scaling healthcare companies. His previous roles include significant tenures at Axogen Inc., McKesson Prescription Technology Solutions, CVS Omnicare, and Express Scripts International. Tamayo's extensive experience in managing global financial operations and preparing companies for IPOs will play a crucial role as Aspargo Labs gears up for entry into public markets. His appointment comes at a transformative time for the company, which specializes in converting medications into liquid oral suspensions—a technology they are currently applying to sildenafil. Michael Demurjian, CEO of Aspargo Labs, emphasized the importance of Tamayo's expertise in optimizing financial operations to align with the strategic goals of the company, particularly as they plan to bring their innovative drug delivery technology to worldwide markets. Tamayo expressed excitement about joining the firm and emphasized their shared commitment to enhancing healthcare accessibility and improving medication adherence through innovative solutions. The announcement highlights Aspargo Labs' focus on leveraging their unique technology platform to transform a variety of medications. However, they also caution that all forward-looking statements in the announcement are subject to risks, including market conditions, regulatory challenges, and potential legal issues.